The NEO | AML Express assay is a next-generation sequencing (NGS) assay using combined DNA- and RNA-sequencing, which is used to identify prognostically and diagnostically informative alterations in acute myeloid leukemia (AML). The DNA sequencing component of this assay detects single nucleotide variants (SNVs) and indels in genes recurrently mutated in AML, and the RNA sequencing component detects fusions involving genes that are frequently involved in structural rearrangements observed in AML, as noted below. Test reports include a summary interpretation of all results together.
DNA Sequencing
- SNVs/InDels (38 genes): ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PRPF8, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
RNA Sequencing
- Fusions (9 genes): ABL1, KAT6A, KMT2A, MECOM, MYH11, NUP98, NUP214, RUNX1, RARA
In conjunction with clinical features and other laboratory results, molecular profiling with the NEO Express AML panel may facilitate risk stratification and therapy selection for patients with newly diagnosed AML.
- Bone Marrow Aspirate: 1-2 mL in EDTA tube
- Peripheral Blood: 2-3 mL in EDTA tube
Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.
Important! To ensure fast TAT and sample stability, ship samples directly to NeoGenomics Houston.
3-5 Days